NewAmsterdam Pharma (NASDAQ:NAMSW) Sees Large Growth in Short Interest

NewAmsterdam Pharma (NASDAQ:NAMSW) was the target of a large increase in short interest during the month of May. As of May 29th, there was short interest totaling 71 shares, an increase of 69.0% from the May 14th total of 42 shares. Based on an average daily volume of 250 shares, the short-interest ratio is currently 0.3 days.

NewAmsterdam Pharma Stock Performance

Shares of NewAmsterdam Pharma stock traded up $2.18 during trading hours on Monday, hitting $20.98. The company’s stock had a trading volume of 12,162 shares, compared to its average volume of 1,951. NewAmsterdam Pharma has a twelve month low of $7.80 and a twelve month high of $30.45. The firm has a fifty day moving average of $22.76 and a 200-day moving average of $22.83.

Hedge Funds Weigh In On NewAmsterdam Pharma

A hedge fund recently bought a new stake in NewAmsterdam Pharma stock. Aristeia Capital L.L.C. bought a new position in shares of NewAmsterdam Pharma (NASDAQ:NAMSW) during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor bought 15,708 shares of the company’s stock, valued at approximately $397,000.

NewAmsterdam Pharma Company Profile

NewAmsterdam Pharma, Inc is a clinical-stage biotechnology company focused on the development of orally delivered peptide therapeutics for the treatment of metabolic diseases. Drawing upon proprietary peptide chemistry and formulation technologies, the company aims to transform injectable treatments for conditions such as type 2 diabetes, obesity and related cardiometabolic disorders into convenient, once-daily oral medications. By harnessing advances in peptide stabilization and targeted delivery, NewAmsterdam Pharma seeks to improve patient adherence and expand access to novel therapies.

The company’s lead program is an oral glucagon‐like peptide‐1 (GLP-1) receptor agonist currently in early clinical trials.